Online Inquiry
Cat.#: ASSD-120
| Description | Competitive fluorescent adenosine receptor antagonist (apparent KD values are 7.50, 7.37 and 7.30 for A2A, A3 and A1 respectively). Antagonizes the activity of NECA, an adenosine receptor agonist. Inhibits cAMP accumulation and stimulates inositol phosphate accumulation (pKb values are 6.4 and 6.5 respectively). Exhibits no intrinsic agonist activity. |
| Synonyms | Fluorescent Adenosine receptor Antagonist (A-633-AN), A-633-AN, XAC-X-BY630 |
| Size | 500 μg |
| Applications | For ligand binding; fluorescence imaging; high content analysis; kinetic analysis; cell sorting at adenosine A1 / A2A / A3 receptors use solutions up to 100 nM. |
| Molecule Weight | 974 |
| Purity | >97% |
| Solubility | Soluble in DMSO |
| Form | Purple solid |
| Excitation | 636 nm |
| Emission | 651 nm |
| Storage | Store at -20° C (protect from light) |
| Shipping | Shipped at 4°C |
| Important | We recommend briefly sonicating the sample when using to ensure it is fully dissolved and the solution is homogeneous. However, we do not recommend using the product after subjecting it to repetitive freeze-thaw cycles. |
| Cat.# | Name | Size | Price |
|---|---|---|---|
| ASSD-166 | FURA-2 (AC166) | 1 mg | inquiry |
| ASSD-184 | BTA-1 (AC184) | 10 mg | inquiry |
| ASSD-187 | Quinaldine Red (AC187) | 5 g, 25 g, 100 g, 250 g | inquiry |
| ASSD-107 | Modified Mayer's Hematoxylin (AC107) | 125 mL, 250 mL, 2×250mL | inquiry |
| ASSD-176 | Rhodamine B isothiocyanate (AC176) | 100 mg, 500 mg | inquiry |
| ASSD-156 | Crystal Violet (AC156) | 1g, 5g | inquiry |
| ASSD-161 | Methylene Blue (AC161) | 50 mg, 1 g | inquiry |
| ASSD-148 | Sulforhodamine 101 (AC148) | 50 mg, 100 mg | inquiry |
| ASSD-200 | Ethylenediamine N-[(Cyanine 3) Monofunctional Hexanoic Acid]-N′-[3-difluoromethyl-4-phosphoanilinamidosuccinic Acid] Diamide (AC200) | 500 μg | inquiry |
| ASSD-102 | DAPI (AC102) | 10 mg, 50 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.